Abstract
We evaluated the efficacy of prophylactic antiglaucoma therapy with timolol maleate ophthalmic solution dis-solved in thermosetting gel in canine primary glaucoma. In the non-treated group (n=23), all dogs had con-firmed glaucoma in the other eye within 24 months of the diagno-sis of glaucoma in the first eye. In the treat-ed group (n=19), however, 53% of dogs had confirmed glaucoma in the other eye by 36 months after diagno-sis in the first eye. The incidence in the treated group was significantly (P<0.01) lower than that in the non-treated group. Dogs in the non-treated group developed glaucoma after a median of 7.7 months, whereas dog sin the treated group developed glaucoma a median of 18.7 months after theonset of glaucoma in the first eye. The median time until the onset of glaucoma in the second eye in the treated group was significantly (P<0.01) longer than that in the non-treated group. This data suggest that prophylactic antiglaucoma therapy with timolol maleate ophthalmic solution dissolved in thermosetting gel is useful for the second eye in canine primary glaucoma.
